Eleven adult patients with nocturnal asthma, and gastro-oesophageal reflux documented by endoscopy or ambulatory oesophageal pH monitoring completed a double-blind cross-over study (4 week treatment, one week run-in and cross-over periods) comparing the effects of omeprazole 20 mg daily and placebo on asthma control assessed by symptoms, peak expiratory flow rate and bronchodilator usage. Omeprazole treatment did not improve asthma symptoms during the day or night, or peak expiratory flow rate readings. There was no difference in bronchodilator inhaler usage during omeprazole therapy.
Introduction
It has been suggested that gastro-oesophageal reflux (GOR) may be an important cause or exacerbating factor in nocturnal asthma, although this is subject to considerable controversy. '-l' Recent studies indicate that 39% of asthmatics have oesophagitis or Barrett's oesophagus"l and 80% of asthmatics have abnormal GOR. '2 Although bronchodilator therapy could lead to GOR, these studies suggest that this high incidence cannot be accounted for by bronchodilator therapy alone. GOR could lead to bronchoconstriction by either micro aspiration directly producing bronchoconstriction, or stimulation of afferent vagal nerves increasing bronchoconstriction or airway responsiveness to extrinsic allergens. 3 
Study design
The study was a double-blind, randomized, crossover trial comparing omeprazole 20 mg once daily with placebo in patients with nocturnal asthma and gastro-oesophageal reflux. The 10-week study period consisted of a one-week run-in followed by two 4-week treatment periods, separated by a one-week wash-out. The primary therapeutic end point studied was peak expiratory flow rate with asthma symptoms and bronchodilator usage as secondary end-points. Patients were seen in the clinic at the end ofthe placebo run-in period (end of week one) and at the end of each treatment period (weeks 5 and 10). At each visit symptoms of day-time asthma (no problems, wheezy for <2 hours a day, wheezy most of day, wheezy all day) and night-time (undisturbed, slept well but woke feeling wheezy, woken 2-3 times a night because of asthma, awake most of night with asthma) were assessed on a scale of 0-3. Patients were issued with diary cards to record day-time and night-time asthma symptoms as above, peak expiratory flow rate (PEFR) on waking before using bronchodilator, PEFR between 4 and 6 pm, on PEFR 30 minutes before retiring to bed, whether trial medication was taken and use of inhaled P2-adrenoceptor agonist drugs. Symptoms were recorded before PEFR was measured. Symptoms of GOR were also recorded at each visit at the end of the run-in, omeprazole and placebo periods. Symptoms were assessed on a scale 0-3 as follows: heartburn (none, occasional episodes not interfering with normal activities, occasional interference with normal activities, and constant interference); and regurgitation (none, occasional on straining or lying down, predictable on position or straining, and pulmonary aspiration manifested by recurrent pneumonia).
Subjects
Eleven patients with nocturnal asthma and evidence of gastro-oesophageal reflux were recruited to the study from respiratory outpatient clinics. Patients (five female, two smokers) had a mean age of 63 (range 50-80) years. Mean weight was 74 (53-109)kg and height 168 (152-180)cm. The duration of asthma symptoms was 11 (0.8-48) years. Duration of nocturnal asthma symptoms was 3.4 (0.7-14) years. The mean duration of GOR symptoms was 52 (7-99) months and the duration of verified reflux oesophagitis was 6.4 (0.1-50) months. One patient withdrew because of uncontrolled asthma symptoms requiring treatment with oral prednisolone (between visits two and three) and was excluded from the analysis. Asthma medication, except for as required inhaled 132-adrenoceptor agonists, was constant for 2 weeks prior to and during the study. Eight patients were taking inhaled steroids and one patient inhaled ipatroprium. Use of antacids but not H2 antagonists, metoclopramide or other anti-reflux drugs was allowed during the study period. Other concomitant medication taken throughout the study was bismuth (two patients), frusemide (1), bendrofluazide (1), amitriptylline (1), metronidazole (1), tetracycline (1) and lorazepam (1 agonists. Full blood count, routine biochemistry and urinalysis were performed prior to study entry; no significant abnormalities were found. Three patients received antibiotic therapy during the study period.
Data analysis
An intention to treat analysis was undertaken, although data from the patient who withdrew because of oral steroid therapy were excluded because of insufficient data in both periods. The methods described by Hills and Armitage were used.24 '25 Results Compliance measured by return tablet counts in the 10 patients who completed the study was 96%. Initial analysis of the data revealed no significant treatment, period or carry-over effects. The results of patient recorded morning PEFR and bronchodilator usage recorded on diary cards daily are shown in Figure 1 . There were no significant differences between placebo and omeprazole therapy for any of the variables assessing asthma symptoms, bronchodilator usage and PEFR. Early morning reduction peak expiratory flow rate remained at around 301/minute throughout the study. PEFR was unchanged by omeprazole on waking (262 ± 86 versus 255 ± 86 I/minute, mean ± s.d., omeprazole versus placebo), during the daytime (293 ± 80 versus 291 ± 81) and at night (280 ± 81 versus 277 ± 78). Night-time (1.0 ± 0.6 versus 1.0 ± 0.7) and day-time (1.0 ± 0.7 versus 0.9 ± 0.7) asthma symptom scores were similarly not altered by omeprazole. Night-time and day-time bronchodilator usage was not significantly reduced by omeprazole (night-time 0.8 ± 1.2 versus 1.0 ± 1.7; day-time 4.7 ± 2.8 versus 6.0 ± 4) (Figure 2) . The statistical power of the test is 29% and the small sample size may have been unable to detect a beneficial treatment effect on day-time bronchodilator use. Results from 20 patients in each group would be required to detect a true difference of 1.2 puffs/day at 80% power and a 5% significance level. Seven of 11 patients recorded a treatment preference for omeprazole and none for placebo (P < 0.01). There was a trend for reflux symptoms to improve during omeprazole therapy. Number of patients with no symptoms in each treatment group was: heartburn (run-in 1, placebo 3, omeprazole 5), regurgitation (run-in 3, placebo 3, omeprazole 3). The changes in GOR symptom scores were not significantly different.
Discussion
The results of this study show no significant improvement in control of nocturnal asthma as assessed by symptoms, PEFR and bronchodilator usage following treatment with omeprazole. Because of the small number of patients studied, a beneficial effect of omeprazole with a small improvement in asthma control with decreased daytime inhaler usage, might not have been detected in this study. We chose to study a highly selected group of asthmatic patients, those with nocturnal symptoms and documented GOR, in the belief that this group ofasthmatic patients were the most likely to have GOR as a significant aetiological factor in producing nocturnal dipping. Our observations argue against GOR being a significant aetiological factor in morning dipping. No significant difference in symptoms ofGOR was found in this study, although this was not a primary endpoint of interest in the study and is almost certainly due to the use of a non-continuous variable in the number of patients studied, unlike the measures of asthma control which were analysed as continuous variables (PEFR readings or mean diary scores over 4 or 7 days). The doubling of patients with no symptoms of heartburn or regurgitation during omeprazole therapy is shorter history of GOR compared to asthma symptoms in our patients would lend support to this concept. Both asthma and GOR are common in the population (approximately 15% and 8% incidence, respectively) and they would be expected to coexist in some individuals, although the high prevalence of GOR documented in studies of unselected asthmatics indicates this cannot be the, sole explanation.''12 Studies of the prevalence of GOR in patients with asthma sugguest more than 80% asthmatics have abnormal GOR. Bronchodilator use may exacerbate GOR, although one study found that bronchodilator therapy did not influence the prevalence of GOR.""2
Our results in conjunction with those ofprevious studies suggest that GOR is at most only a minor factor in exacerbating asthma symptoms. Ekstrom et al. found that a history of reflux associated symptoms appeared to be the only factor that identified which patients' asthma would benefit from treatment for GOR.14 Case reports suggest that in individual patients GOR may be a major causative factor in producing bronchoconstriction, although in many of these cases GOR was severe and gross aspiration may have occurred. Despite the association between asthma and GOR, our results in conjunction with previous studies suggest that routine investigation for GOR in asthmatic patients is not indicated, as treatment of GOR is unlikely to result in significant improvement in asthma control.
